- RAPAFLO(R) demonstrated significant response in men with moderate to severe CP/CPPS - WASHINGTON, May 17, 2011 /PRNewswire/ -- New data presented today show that RAPAFLO(R) (silodosin) significantly ...

BPH is one of those conditions that affects a large population and has physical symptomology that makes sufferers very uncomfortable. These facts make it a great condition for DTC. Unfortunately, ...

RAPAFLO (Silodosin) 4mg, 8mg capsules by Watson Watson has launched Rapaflo (silodosin capsules), a selective alpha-1 adrenergic receptor antagonist, for the treatment of the signs and symptoms of ...

RAPAFLO (Silodosin) 4mg, 8mg capsules by Watson The FDA has approved Rapaflo (silodosin, from Watson) for the treatment of benign prostatic hyperplasia (BPH). The FDA has approved Rapaflo (silodosin, ...

CORONA, Calif., Oct. 9 Watson Pharmaceuticals,Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced todaythat the U.S. Food and Drug Administration (FDA) has approved ...

WASHINGTON, Oct. 13 (UPI) -- The U.S. Food and Drug Administration has approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia. "Benign prostatic ...

A website indicating that Actavis’s alpha-blocker Rapaflo capsules can improve sleep and daytime productivity prompted an untitled letter from the FDA’s Office of Prescription Drug Promotion. The drug ...

Novadoz Pharmaceuticals has received the Food and Drug Administration’s clearance to market silodosin in 4-mg and 8-mg capsules. The product is the generic of Allergan’s Rapaflo. Silodosin is ...

NEW YORK, Oct 8 (Reuters) - U.S. health regulators have approved Watson Pharmaceuticals Inc's Rapaflo treatment for urination problems -- a condition known as benign prostatic hyperplasia (BPH), the ...

Oct. 10 -- THURSDAY, Oct. 9 (HealthDay News) -- The once-daily alpha blocker Rapaflo (silodosin) has been approved by the U.S. Food and Drug Administration to treat benign prostatic hyperplasia (BPH), ...

PARSIPPANY, N.J., June 19, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) and Kissei Pharmaceutical Co., LTD today confirmed that they have filed lawsuits against Sandoz Inc., Hetero USA, Inc., Hetero ...

CORONA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the U.S. Food and ...